AGL vs FBRX
AGL: Agilon empowers primary care physicians to take financial and clinical risk for managing total healthcare costs under Medicare capitation, using technology and data to drive quality and profitability. FBRX: A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data and trials underway in vitiligo and alopecia areata.
Side-by-side fundamentals
| Metric | AGL | FBRX | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $100.27 | $59.70 | |
| Market cap as of 2026-07-24 | $2.0B | $1.3B | |
| PEG as of 2026-07-24 | -0.12 | n/a | |
| Net margin as of 2026-07-24 | -6.1% | -158775.0% | AGL higher |
| Gross margin as of 2026-07-24 | -0.4% | n/a | |
| Operating margin as of 2026-07-24 | -7.5% | -150175.0% | AGL higher |
| ROE as of 2026-07-24 | -138.6% | -106.2% | FBRX higher |
| ROA as of 2026-07-24 | -23.3% | -85.5% | AGL higher |
| Debt / equity as of 2026-07-24 | 0.17 | 0.00 | FBRX lower |
| Revenue growth (YoY) as of 2026-07-24 | -2.8% | -99.8% | AGL higher |
| Revenue CAGR (3y) SEC XBRL | +35.4% | -9.8% | AGL higher |
| Beta as of 2026-07-24 | 3.03 | 2.80 | |
| 1-year return as of 2026-07-23 close | +120.0% | +443.0% | FBRX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.